A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2018
At a glance
- Drugs Durvalumab (Primary) ; Neoantigen DNA vaccine MedImmune/Washington University School of Medicine (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 24 Apr 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 Planned End Date changed from 31 Jan 2021 to 31 Mar 2021.
- 07 Mar 2018 Planned primary completion date changed from 31 Jul 2020 to 30 Sep 2020.